医用大麻治疗慢性疼痛的心血管安全性:丹麦全国性研究
结果显示,医用大麻使用与180天内新发心律失常风险升高相关(0.8% vs 0.4%,风险比2.07),而急性冠脉综合征风险未见显著关联。
要点
- 慢性疼痛患者首次使用医用大麻后180天内新发心律失常绝对风险为0.8%,高于未使用者的0.4%。
- 180天心律失常风险比为2.07(95%CI 1.34-2.80),1年风险比为1.36(95%CI 1.00-1.73)。
- 急性冠脉综合征风险未见显著关联(180天风险比1.20,95%CI 0.35-2.04)。
核心结论
- 在慢性疼痛患者中,使用处方医用大麻与未使用相比与新发心律失常风险升高相关,在开始治疗后180天内最为明显。
主要发现
- 180天内心律失常分别见于医用大麻组42例和对照组107例。
- 医用大麻组180天新发心律失常绝对风险0.8%(95%CI 0.6%-1.1%),未使用组0.4%(95%CI 0.3%-0.5%)。
- 180天心律失常风险比2.07(95%CI 1.34-2.80),1年风险比1.36(95%CI 1.00-1.73)。
- 急性冠脉综合征未见显著关联,180天风险比1.20(95%CI 0.35-2.04)。
临床怎么用
- 对慢性疼痛患者处方医用大麻时,应关注开始治疗后尤其前180天的新发心律失常风险,并做好心律监测与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: A rising number of countries allow physicians to treat chronic pain with medical cannabis. However, recreational cannabis use has been linked with cardiovascular side effects, necessitating investigations concerning the safety of prescribed medical cannabis. METHODS: Using nationwide Danish registers, patients with chronic pain initiating first-time treatment with medical cannabis during 2018-21 were identified and matched 1:5 to corresponding control patients on age, sex, chronic pain diagnosis, and concomitant use of other pain medication. The absolute risks of first-time arrhythmia (atrial fibrillation/flutter, conduction disorders, paroxysmal tachycardias, and ventricular arrhythmias) and acute coronary syndrome were reported comparing medical cannabis use with no use. RESULTS: Among 1.88 million patients with chronic pain (46% musculoskeletal, 11% cancer, 13% neurological, and 30% unspecified pain), 5391 patients claimed a prescription of medical cannabis [63.2% women, median age: 59 (inter-quartile range 48-70) years] and were compared with 26 941 control patients of equal sex- and age composition. Arrhythmia was observed in 42 and 107 individuals, respectively, within 180 days. Medical cannabis use was associated with an elevated risk of new-onset arrhythmia {180-day absolute risk: 0.8% [95% confidence interval (CI) 0.6%-1.1%]} compared with no use [180-day absolute risk: 0.4% (95% CI 0.3%-0.5%)]: a risk ratio of 2.07 (95% CI 1.34-2.80) and a 1-year risk ratio of 1.36 (95% CI 1.00-1.73). No significant association was found for acute coronary syndrome [180-day risk ratio: 1.20 (95% CI 0.35-2.04)]. CONCLUSIONS: In patients with chronic pain, the use of prescribed medical cannabis was associated with an elevated risk of new-onset arrhythmia compared with no use-most pronounced in the 180 days following the initiation of treatment.
引用
- Holt, Nouhravesh, Strange, et al. Cannabis for chronic pain: cardiovascular safety in a nationwide Danish study. Eur Heart J. 2024. PMID: 38200679. doi:10.1093/eurheartj/ehad834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。